Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aurinia Pharmaceuticals Inc (AUP.TO)

Aurinia Pharmaceuticals Inc (AUP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aurinia Pharmaceuticals Inc 14315 118 Avenue Suite 140 Edmonton AB T5L 4S6 CAN

https://www.auriniapharma.com P: 250-708-4272 F: 604-369-4115

Description:

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Key Statistics

Overview:

Market Capitalization, $K 2,147,902
Shares Outstanding, K 128,396
Annual Sales, $ 175,513 K
Annual Net Income, $ -78,020 K
Last Quarter Sales, $ 67,771 K
Last Quarter Net Income, $ 14,350 K
60-Month Beta 0.26
% of Institutional Shareholders 19.44%

Growth:

1-Year Return -6.73%
3-Year Return 141.50%
5-Year Return 255.84%
5-Year Revenue Growth 227.90%

Per-Share Information:

Next Earnings Date 08/05/21
Earnings Per Share ttm -1.16
Dividend Payout Ratio 0.00%
Most Recent Split 1-50 on 10/23/13

AUP.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -5.78%
Return-on-Assets % -4.08%
Profit Margin % -44.45%
Debt/Equity 0.22
Price/Sales 32.26
Price/Book 4.67
Book Value/Share 3.59
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar